SCHEMBL9215880

SCHEMBL9215880

Clc1ccc(-c2ccc[nH]2)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.47
PIK3CD O00329 1/20 0.46
NPC1 O15118 3/20 0.42
RAB9A P51151 2/20 0.42
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
NOTUM Q6P988 1/20 0.40
KDR P35968 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CHRNB2 P17787 2/20 0.36
CHRNA7 P36544 1/20 0.36
CHRNA4 P43681 1/20 0.36
CHRNA3 P32297 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30354463 0.77 HPGDS (0.53) CYP2A6PIK3CDNPC1RAB9AKDR
SCHEMBL16059998 0.77 HPGDS (0.53) CYP2A6PIK3CDNPC1RAB9AKDR
SCHEMBL30354464 0.77 HPGDS (0.53) CYP2A6PIK3CDNPC1RAB9AKDR
SCHEMBL1662273 0.73 PIK3CD (0.73) CYP2A6PIK3CDNPC1RAB9AALDH1A1
SCHEMBL9419852 0.73 HDAC6 (0.57) KDRHDAC1HDAC6
SCHEMBL23417016 0.73 TRPV4 (0.44) PIK3CDKDRHDAC1HDAC6
SCHEMBL20852325 0.73 PRMT5 (0.37) KDRHDAC1HDAC6
SCHEMBL28893597 0.73 EGLN2 (0.42) PIK3CDKDRHDAC1HDAC6
SCHEMBL198093 0.73 CNR1 (0.49) CYP2A6NPC1RAB9AALDH1A1KDM4E
SCHEMBL6224732 0.72 IDO1 (0.49) NOTUMMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230058961-A1 SUBSTITUTED HETEROCYCLICS WITH THERAPEUTIC ACTIVITY IN HIV NATIONAL INSTITUTES OF HEALTH 2023-02-23 US disclosed
CN-114727987-A Substituted heterocyclic compounds having HIV therapeutic activity 纽约血库公司 2022-07-08 CN disclosed
WO-2021102114-A1 SUBSTITUTED HETEROCYCLICS WITH THERAPEUTIC ACTIVITY IN HIV NEW YORK BLOOD CENTER, INC. (US) 2021-05-27 WO disclosed
WO-1995000506-A1 SUBSTITUTED PYRIDYLPYRROLES AND THEIR USE FOR CONTROLLING ANIMAL PESTS BAYER AKTIENGESELLSCHAFT (DE) 1995-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230058961-A1 SUBSTITUTED HETEROCYCLICS WITH THERAPEUTIC ACTIVITY IN HIV CD4, NFATC1, PAICS CYP2A6 295/4885PIK3CD 2236/4885NPC1 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.